ITP - ifosfamide, paclitaxel, and cisplatin; EP – etoposide/platinum; IA-EP – ifosfamide/Adriamycin-EP; Gem-FLP – gemcitabine, 5-FU, leucovorin, cisplatin. This is an ASCO Meeting Abstract from the ...

Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

The impact of the Area Deprivation Index on immunotherapy outcomes in metastatic renal cell carcinoma (mRCC). This is an ASCO Meeting Abstract from the 2025 ASCO Genitourinary Cancers Symposium. This ...

Cade, Telix Group Chief Medical Officer, said, “Telix will feature in four presentations at this year’s ASCO GU, which showcase the depth and differentiation of our therapeutic urologic pipeline, ...

Proactive onco-coaching did not improve quality of life but was linked to better overall survival in patients with metastatic ...

CHENGDU, China, Feb. 12, 2025 /PRNewswire/ -- At the American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2025, to be held in San Francisco, USA, from Feb. 13-15, 2025, ...

Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) Cancers Symposium. The Dana-Farber led research exemplifies innovative and ...

NEW YORK, January 28, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) will present the latest results from its leading genitourinary (GU) portfolio at the American Society of Clinical Oncology ...

Patient-reported outcomes (PROs) were similar among those treated with tivozanib monotherapy and those given combination ...

A recent meta-analysis shows that acute toxicities following radiation therapy signal a greater risk for later complications in patients with prostate cancer.